Non - dilutive funding

搜索文档
RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease
Prnewswire· 2025-07-21 21:00
The positive FDA feedback allows for: A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium subspecies paratuberculosis infected (MAP-positive) Crohn's disease (CD) patient population Groundbreaking approach testing MAP as a root cause of CD, supporting RHB-204 as a potential paradigm-shifting therapy treating both the suspected cause of Crohn's disease and its symptoms RedHill has initiated two new collaborations with leading academic c ...
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
Globenewswire· 2025-07-17 21:00
文章核心观点 - OKYO Pharma获190万美元非稀释性资金支持研发,将加速核心候选药物urcosimod临床开发,推进关键临床里程碑,且不影响现有股东权益 [1][2] 关于NCP - 神经性角膜疼痛(NCP)会致眼、脸或头部剧痛和敏感,病因不明,或由角膜神经损伤与炎症共同导致 [4] - 目前该疾病无FDA批准药物,患者使用各种局部和全身治疗药物进行非适应症治疗 [4] 关于Urcosimod - Urcosimod是一种脂质共轭趋化素肽激动剂,采用膜锚定肽技术开发,旨在治疗眼部疾病 [5] - 该药物在干眼症和角膜神经性疼痛小鼠模型中分别展现出抗炎和止痛活性,并通过脂质锚增强在眼部环境中的疗效 [5] - 在240名患者参与的2期干眼症试验多个终点有显著统计学意义,刚完成治疗神经性角膜疼痛的2期试验 [5] 关于OKYO - OKYO Pharma是一家临床阶段生物制药公司,专注开发治疗神经性角膜疼痛和干眼症的创新疗法,普通股在纳斯达克资本市场交易 [6] - 公司刚完成urcosimod治疗神经性角膜疼痛患者的2期试验 [6]